Latest results FY2025 · Prices updated Oct 30, 2026
HQ: Tokyo, TokyoFounded 199050 employeesWebsite
A biopharmaceutical company specializing in drug discovery targeting GPCRs. It applies its proprietary discovery platform to develop drug candidates and collaborates with pharmaceutical companies worldwide.
Business segments (share of revenue)
Latest results
FY2025
vs. same period a year earlier
Company forecastFY2026
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Pharmaceutical Business | 100% | ¥29.6B | ¥-8.5B | -28.6% |
Close (Oct 30, 2026)
¥1,440+58.2% (1Y)
Nxera +58.2% over 1Y, 47.4pt above the industry average (23 companies, +10.9%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2025FY | ¥29.6B | ¥-8.5B | ¥-12.5B | ¥134.8B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Jan 2026)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
